CTS1: A p53-derived chimeric tumor suppressor gene with enhanced in vitro apoptotic properties

Journal of Clinical Investigation

Volumn 101, Issue 1, 1998, Pages 120-127

  Conseiller, Emmanuel ^a   Debussche, Laurent ^a   Landais, Didier ^a   Venot, Corinne ^a   Maratrat, Michel ^a   Sierra, Veronique ^a   Tocque, Bruno ^a   Bracco, Laurent ^a  

^a SANOFI   (France)

Author keywords

Apoptosis; Cancer; Gene therapy; mdm2; p53

Indexed keywords

CHIMERIC TUMOR SUPPRESSOR 1; PROTEIN P53; SUPPRESSOR FACTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL GROWTH; CHIMERA; GENE THERAPY; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; QUANTITATIVE DIAGNOSIS; TRANSCRIPTION REGULATION; TUMOR SUPPRESSOR GENE;

EID: 0031964433     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI1140     Document Type: Article

References (49)

1. Barbacid, M. 1987. ras genes. Annu. Rev. Biochem. 56:779-827.
2. Hollstein, M., D. Sidransky, B. Vogelsrein, and C.C. Harris. 1991. p53 mutations in human cancers. Science. 253:49-53.
3. Fujiwara, T., D. Cai, R.N. Georges, T. Mukhopadhyay, E.A. Grimm, and J.A. Roth. 1994. Therapeutic effect of a retroviral wild-type p53 expression vector in an orthotopic lung cancer model. J. Natl. Cancer Sci. 86:1458-1462.
4. Clayman, G.L., A.K. el-Naggar, J.A. Roth, W.W. Zhang, H. Goepfert, D.L. Taylor, and T.J. Liu. 1995. In vivo molecular therapy with p53 adenovirus for microscopic residual head and neck squamous carcinoma. Cancer Res. 55:1-6.
5. Milner, J., E.A. Medcalf, and A.C. Cook. 1991. Tumor suppressor p53: analysis of wild-type and mutant p53 complexes. Mol. Cell. Biol. 11:12-19.
6. Milner, J., and E.A. Medcalf. 1991. Cotranslation of activated mutant p53 with wild-type drives the wild-type p53 into the mutant conformation. Cell. 65: 765-774.
7. Oliner, J.D., K.W. Kinzler, P.S. Meltzer, D. George, and B. Vogelstein. 1992. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature. 358:80-83.
8. Leach, F.S., T. Tokino, P. Meltzer, M. Burrell, J.D. Oliner, S. Smith, D.E. Hill, D. Sidransky, K.W. Kinzler, and B. Vogelstein. 1993. p53 mutation and mdm2 amplification in human soft tissue sarcomas. Cancer Res. 53:2231-2234.
9. Gorgoulis, V.G., G.Z. Rassidakis, A.M. Karameris, H. Papastamatiou, R. Trigidou, M. Veslemes, A.N. Rassidakis, and C. Kittas. 1996. Immunohistochemical and molecular evaluation of the mdm-2 gene product in bronchogenic carcinoma. Mod. Pathol. 9:544-554.
10. Momand, J., G.P. Zambetti, D.C. Olson, D. George, and A.J. Levine. 1992. The mdm-2 oncogene product forms complex with the p53 protein and inhibits p53 mediated transactivation. Cell. 69:1237-1245.
11. Oliner, J.D., J.A. Pietenpol, S. Thiagalingam, J. Gyuris, K.W. Kinzler, and B. Vogelstein. 1993. Oncoprotein MDM2 conceals the activation domain of tumor suppressor p53. Nature. 362:857-860.
12. Finlay, C.A. 1993. The mdm-2 oncogene can overcome wild-type p53 suppression of transformed cell growth. Mol. Cell. Biol. 13:301-306.
13. Haupt, Y., R. Maya, A. Kazaz, and M. Oren. 1997. Mdm2 promotes the rapid degradation of p53. Nature. 387:296-299.
14. Kubbutal, M.H., S.N. Jones, and K.H. Vousden. 1997. Regulation of p53 stability by Mdm2. Nature. 387:299-303.
15. Scheffner, M., B.A. Werness, J.M. Huibregtse, A.J. Levine, and P.M. Howley. 1990. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes degradation of p53. Cell 63:1129-1136.
16. Hubbert, N.L., S.A. Sedman, and J.T. Schiller. 1992. Human papillomavirus type 16 E6 increases the degradation rate of p53 in human keratinocytes. J. Virol. 66:6237-6241.
17. Fields, S., and S. Jang. 1990. Presence of a potent transcription activating sequence in the p53 protein. Science. 249:1046-1049.
18. Horikoshi, N., A. Usheva, J. Chen, A.J. Levine, R. Weinmann, and T. Shenk. 1995. Two domains of p53 interact with the TATA-binding protein, and adenovirus 13S E1A protein disrupts the association, relieving p53-mediated transcriptional repression. Mol. Cell. Biol. 15:227-234.
19. Szekely, L., G. Selinova, K.P. Magnusson, G. Klein, and K.G. Wiman. 1993. EBNA-5, an Epstein-Barr virus-encoded nuclear antigen, binds to the retinoblastoma and p53 proteins. Proc. Natl. Acad. Sci. USA. 90:5455-5459.
20. Sarnow, P., Y.S. Ho, J. Williams, and A.J. Levine. 1982. Adenovirus E1b-58kd tumor antigen and SV40 large tumor antigen are physically associated with the same 54 kd cellular protein in transformed cells. Cell. 28:387-394.
21. Pavletich, N.P., K.A. Chambers, and C.O. Pabo. 1993. The DNA-binding domain of p53 contains the four conserved regions and the major mutation hot spots. Genes Dev. 7:2556-2564.
22. Bargonetti, J., J.J. Manfredi, X. Chen, D.R. Marshak, and C. Prives. 1993. A proteolytic fragment from the central region of p53 has marked sequence-specific DNA-binding activity when generated from wild-type but not from oncogenic mutant p53 protein. Genes Dev. 7:2565-2574.
23. Cho, Y., S. Gorina, P.D. Jeffrey, and N.P. Pavletich. 1994. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science. 265:346-355.
24. Soussi, T., C. Caron de Fromentel, and P. May. 1990. Structural aspects of the p53 protein in relation to gene evolution. Oncogene. 5:945-952.
25. Clore, G.M., J.G. Omichinski, K. Sakaguchi, N. Zambrano, H. Sakamoto, E. Appella, and A.M. Gronenborn. 1994. High-resolution structure of the oligomerization domain of p53 by multidimensional NMR. Science. 265: 386-391.
26. Jeffrey, P.D., S. Gorina, and N.P. Pavletich. 1995. Crystal structure of the tetramerization domain of the p53 tumor suppressor at 1.7 Angstroms. Science. 267:1498-1502.
27. Clore, G.M., J.G. Omichinski, K. Sakaguchi, N. Zambrano, H. Sakamoto, E. Appella, and A.M. Gronenborn. 1995. Interhelical angles in the solution structure of the oligomerization domain of p53: correction. Science. 267: 1515-1516.
28. Dobner, T., N. Horikoshi, S. Rubenwolf, and T. Shenk. 1996. Blockage by adenovirus E4orf6 of transcriptional activation by the p53 tumor suppressor. Science. 272:1470-1473.
29. Moore, M., N. Horikoshi, and T. Shenk. 1996. Oncogenic potential of the adenovirus E4orf6 protein. Proc. Natl. Acad. Sci. USA. 93:11295-11301.
30. Hupp, T.R., D.W. Meek, C.A. Midgley, and D.P. Lane. 1992. Regulation of the specific DNA-binding function of p53. Cell. 71:875-886.
31. el-Deiry, W.S., T. Tokino, V.E. Velculescu, D.B. Levy, R. Parsons, J.M. Trent, D. Lin, W.E. Mercer, K.W. Kinzler, and B. Vogelstein. 1993. WAFI, a potential mediator of p53 tumor suppression. Cell. 75:817-825.
32. Leveillard, T., L. Andera, N. Bissonnette, L. Schaeffer, L. Bracco, J.M. Egly, and B. Wasylyk. 1996. Functional interactions between p53 and the TFIIH complex are affected by the tumour-associated mutations. EMBO (Eur. Mol. Biol. Organ.) J. 15:1615-1623.
33. Funk, W.D., D.T. Pak, R.H. Karas, W.E. Wright, and J.W. Shay. 1992. A transcriptionally active DNA-binding site for human p53 protein complexes. Mol. Cell. Biol. 12:2866-2871.
34. Dubs-Poterszman, M.C., B. Tocque, and B. Wasylyk. 1995. MDM2 transformation in the absence of p53 and abrogation of the p107 G1 cell-cycle arrest. Oncogene. 11:2445-2449.
35. 4. Nature. 227:680-685.
36. Herrmann, M., H.M. Lorenz, R. Voll, M. Grunke, W. Woith, and J.R. Kalden. 1994. A rapid and simple method for the isolation of apoptotic DNA fragments. Nucl. Acids Res. 22:5506-5507.
37. el-Deiry, W.S., K.E. Kern, J.A. Pietenpol, K.W. Kinzler, and B. Vogelstein. 1992. Definition of a consensus binding site for p53. Nat. Genet. 1:45-49.
38. Friedman, P.N., X. Chen, J. Bargonetti, and C. Prives. 1993. The p53 protein is an unusually shaped tetramer that binds directly to DNA. Proc. Natl. Acad. Sci. USA. 90:3319-3323.
39. Shaw, P., R. Bovey, S. Tardy, R. Sahli, B. Sordat, and J. Costa. 1992. Induction of apoptosis by wild-type p53 in human colon tumor-derived cell line. Proc. Natl. Acad. Sci. USA. 89:4495-4499.
40. Zauberman, A., D. Flusberg, Y. Haupt, Y. Barak, and M. Oren. 1995. A functional p53-responsive intronic promoter is contained with the human mdm2 sene. Nucl. Acids Res. 23:2584-2542.
41. Masuda, H., C. Miller, H.P. Koeffler, H. Battifora, and M.J. Cline. 1987. Rearrangement of the p53 gene in human osteogenic sarcomas. Proc. Natl. Acad. Sci. USA. 84:7716-7719.
42. Mietz, J.A., T. Unger, J.M. Huibregtse, and P.M. Howley. 1992. The transcriptional transactivation function of wild-type p53 is inhibited by SV40 large T-antigen and by HPV-16 E6 oncoprotein. EMBO (Eur. Mol. Biol. Organ.) J. 11:5013-5020.
43. Haupt, Y., Y. Barak, and M. Oren. 1996. Cell type-specific inhibition of p53-mediated apoptosis by mdm2. EMBO (Eur. Mol. Biol. Organ.) J. 15:1596-1606.
44. 1 arrest and apoptosis functions of the p53 tumor suppressor protein. Mol. Cell. Biol. 16:2445-2452.
45. Gannon, J.V., R. Greaves, R. Iggo, and D. Lane. 1990. Activating mutations in p53 produce common conformational effects: a monoclonal antibody specific for the mutant form. EMBO (Eur. Mol. Biol. Organ.) J. 9:1595-1602.
46. Pietenpol, J.A., T. Tokino, S. Thiagalingam, W.S. el-Deiry, K.W. Kinzler, and B. Vogelstein. 1994. Sequence-specific transcriptional activation is essential for growth suppression by p53. Proc. Natl. Acad. Sci. USA. 91:1998-2002.
47. Attardi, L.D., S.W. Lowe, J. Brugarolas, and T. Jacks. 1996. Transcriptional activation by p53, but not induction of the p21 gene, is essential for oncogene-mediated apoptosis. EMBO (Eur. Mol. Biol. Organ.) J. 15:3693-3701.
48. Waterman, M.J.F., J.L.F. Waterman, and T.D. Halazonetis. 1996. An engineered four-stranded coiled coil substitutes for the tetramerization domain of wild-type p53 and alleviates transdominant inhibition by tumor-derived p53 mutants. Cancer Res. 56:158-163.
49. Dedieu, J.F., E. Vigne, J.M. Guillaume, M. Perricaudet, and P. Yeh, 1996. E1/E4 doubly defective adenoviruses are severely impaired for viral DNA accumulation and late gene expression in non-complementing cells. Cold Spring Harbor Gene Therapy Meeting, Cold Spring Harbor, NY. 25-29 September 1996 (Abstr.).